The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Circulating Inflammation Markers and Prospective Risk for Lung Cancer
Open accessAbstract
BACKGROUND: Despite growing recognition of an etiologic role for inflammation in lung carcinogenesis, few prospective epidemiologic studies have comprehensively investigated the association of circulating inflammation markers with lung cancer. METHODS: We conducted a nested case-control study (n = 526 lung cancer patients and n = 592 control subjects) within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Control subjects were matched to lung cancer case patients on age, sex, follow-up time (median = 2.9 years), randomization year, and smoking (pack-years and time since quitting). Serum levels of 77 inflammation markers were measured using a Luminex bead-based assay. Conditional logistic regression and weighted Cox models were used to estimate odds ratios (ORs) and cumulative risks, respectively. RESULTS: Of 68 evaluable markers, 11 were statistically significantly associated with lung cancer risk (P trend across marker categories < .05), including acute-phase proteins (C-reactive protein [CRP], serum amyloid A [SAA]), proinflammatory cytokines (soluble tumor necrosis factor receptor 2 [sTNFRII]), anti-inflammatory cytokines (interleukin 1 receptor antagonist [IL-1RA]), lymphoid differentiation cytokines (interleukin 7 [IL-7]), growth factors (transforming growth factor alpha [TGF-A]), and chemokines (epithelial neutrophil-activating peptide 78 [ENA 78/CXCL5], monokine induced by gamma interferon [MIG/CXCL9], B cell-attracting chemokine 1 [BCA-1/CXCL13], thymus activation regulated chemokine [TARC/CCL17], macrophage-derived chemokine [MDC/CCL22]). Elevated marker levels were associated with increased lung cancer risk, with odds ratios comparing the highest vs the lowest group ranging from 1.47 (IL-7) to 2.27 (CRP). For IL-1RA, elevated levels were associated with decreased lung cancer risk (OR = 0.71; 95% confidence interval = 0.51 to 1.00). Associations did not differ by smoking, lung cancer histology, or latency. A cross-validated inflammation score using four independent markers (CRP, BCA-1/CXCL13, MDC/CCL22, and IL-1RA) provided good separation in 10-year lung cancer cumulative risks among former smokers (quartile [Q] 1 = 1.1% vs Q4 = 3.1%) and current smokers (Q1 = 2.3% vs Q4 = 7.9%) even after adjustment for smoking. CONCLUSIONS: Some circulating inflammation marker levels are associated with prospective lung cancer risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064 · cited 1×
“Indeed, despite substantial reductions in lung cancer mortality through low-dose computed tomography screening (40), the high false-positivity rate of this screening modality underscores”
BackgroundIl'yasova, D., Colbert, L. H., Harris, T. B., Newman, A. B., Bauer, D. C., Satterfield, S., & Kritchevsky, S. B. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0316 · Cited by 479
Cited by
Why Sleep Is Important for Health: A Psychoneuroimmunology Perspective
Irwin, M. R. (2015) · Annual Review of Psychology · doi:10.1146/annurev-psych-010213-115205 · Cited by 1,325
“…liver, and prostate (Ko et al. 2012), especially in men (Baune et al. 2011), with other data showing that inflammation is linked to breast cancer incidence (Touvier et al. 2013) and interacts with other factors (e.g., smoking) to increase lung cancer risk (Shiels et al. 2013, Siemes et al. 2006).”
BackgroundCXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond
Kazanietz, M. G., Durando, M., & Cooke, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00471 · Cited by 356
Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers
Shiels, M. S., Katki, H. A., Freedman, N. D., Purdue, M. P., Wentzensen, N., Trabert, B., Kitahara, C. M., Furr, M., Li, Y., Kemp, T. J., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju294 · Cited by 322
Self-citationKing, P. T. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0068-z · Cited by 269
Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer
Haston, S., Gonzalez-Gualda, E., Morsli, S., Ge, J., Reen, V., Calderwood, A., Moutsopoulos, I., Panousopoulos, L., Deletic, P., Carreno, G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.004 · Cited by 251
Metadata
- Authors
- Shiels, M. S., Pfeiffer, R. M., Hildesheim, A., Engels, E. A., Kemp, T. J., Park, J.-H., Katki, H. A., Koshiol, J., Shelton, G., Caporaso, N. E., Pinto, L. A., & Chaturvedi, A. K.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-18
- Volume
- 105
- Issue
- 24
- Pages
- 1871-1880
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2107092018
- Cited by
- 222
- References
- 3
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating Inflammation Markers and Prospective Risk for Lung Cancer. https://app.cochat.ai/papers/10.1093/jnci/djt309
- The paper
- Shiels, M. S., Pfeiffer, R. M., Hildesheim, A., Engels, E. A., Kemp, T. J., Park, J.-H., Katki, H. A., Koshiol, J., Shelton, G., Caporaso, N. E., Pinto, L. A., & Chaturvedi, A. K. (2013). Circulating Inflammation Markers and Prospective Risk for Lung Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djt309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.